Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Oct 09, 2024 12:23pm
87 Views
Post# 36259532

RE:RE:RE:RE:Medipharm Labs Big Win

RE:RE:RE:RE:Medipharm Labs Big Win
CADInvestor12 wrote: they did indicate B2B & Dronabinol impact .. taken directly from Q4 transcript ... 

"we have seen renewed interest regarding B2B quality-focused manufacturing opportunity. Together, these deals could represent over $10 million in annual revenue potential."

 "The most exciting development in Germany in Q4 was the commercialization of our natural Dronabinol product. We believe that our natural GMP Dronabinol manufacturing and selling process is unique to MediPharm and is industry-leading in mitigating risk of quality and oxidization issues. The scale allows us to be competitive on current industry pricing while maintaining healthy margins. In 2024, Dronabinol will be a big part of our growth in German sales. In 2023, we sold just under $100,000 of this product, mostly for partner R&D. At this point, in 2024, we have already shipped this product to 3 customers and our sales and open orders are already over $1.5 million."



Certainly they made mention of those two, but it wasn't a strategic focus and neither really were on the radar up until that point.  Sometimes things falling into your lap is a great thing, that said, until the drob business can be backed up by sustainable and concrete POs/long term supply agreements, that revenue kicker can go as quickly as it came.  If Medipharm is the only game in town for drob, you'd think it wouldn't be hard to ink a couple of supply contracts with guaranteed volumes for say a 3-5 year term. 
<< Previous
Bullboard Posts
Next >>